论文部分内容阅读
以￣（３５）Ｓ标记抗人脑胶质瘤单克隆抗体ＳＺ３９制备成导向放疗剂￣（３５）Ｓ－ＭＡｂＳＺ３９，荷瘤鼠体内治疗研究表明１０３．６ＭＢｑ￣（３５）Ｓ－ＭＡｂ￣（３５）ＳＺ３９对肿瘤可产生抑制作用，阻制肿瘤生长一周左右，给药后２６天，抑制率达５０％．流式细胞计数仪分析，导向治疗后肿瘤细胞ＤＮＡ合成受抑，Ｓ期细胞蓄积，Ｇ１期细胞受阻，有细胞周期同步化趋势，有利于再次导向放射治疗。病理学检查证实，￣（３５）Ｓ－ＭＡｂ￣（３５）ＳＺ３９对脊髓正常组织无明显毒付作用。以上结果显示了￣（３５）Ｓ－ＭＡｂ￣（３５）ＳＺ３９对人脑胶质瘤放射免疫治疗的潜在价值。
A 35S-labeled anti-human glioma monoclonal antibody SZ39 was prepared as a directed radiotherapy agent ̄(35)S-MAbSZ39. In vivo treatment studies in tumor-bearing mice showed 103.6MBq ̄(35)S-MAb ̄ (35 ) SZ39 can inhibit the growth of tumors, inhibit tumor growth for about one week, and after 26 days of administration, the inhibition rate reaches 50%. Flow cytometric analysis showed that DNA synthesis of tumor cells was inhibited after targeted treatment, cell accumulation was observed in S phase, G1 phase cells were blocked, and cell cycle synchronization was observed, which was conducive to redirected radiation therapy. Pathological examination confirmed that ̄(35)S-MAb ̄(35)SZ39 had no obvious toxic effect on normal spinal cord tissue. The above results show the potential value of ̄(35)S-MAb ̄(35)SZ39 for radioimmunotherapy of human glioma.